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The data presented in this article relates to the manuscript entitled
‘Engineering of Chinese hamster ovary cell lipid metabolism re-
sults in an expanded ER and enhanced recombinant biotherapeutic
protein production’, published in the Journal Metabolic Engineer-
ing [1]. In the article here, we present data examining the over-
expression of the lipid metabolism modifying genes SCD1 and
SREBF1 in CHO cells by densitometry of western blots and by using
mass spectrometry to investigate the impact on speciﬁc lipid
species. We also present immunoﬂuorescence data at the protein
level upon SCD1 and SREBF1 overexpression. The growth proﬁle
data during batch culture of control CHO cells and CHO cells
engineered to overexpress SCD1 and SREBF1 during batch culture
are also reported. Finally, we report data on the yields of model
secretory recombinant proteins produced from control, SCD1 or
SREBF1 engineered cells using a transient expression systems.
© 2020 The Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).j.ymben.2019.11.007.
ales).
lsevier Inc. This is an open access article under the CC BY license (http://
Speciﬁcations Table
Subject Biotechnology
Speciﬁc subject area Lipid Metabolism Metabolic Engineering and Recombinant Protein Expression from
CHO Cells





How data were acquired Viable cell concentration and culture viability measurements were collected on a ViCell
instrument (Beckman Coulter).
Secreted recombinant protein concentrations in cell culture supernatants were
determined using an Octet® instrument (ForteBio) with IgG calibrators and protein A
biosensors.
Western blot analysis was undertaken on standard laboratory equipment.
Microscopy images were collected on a Zeiss LSM 880/Elyra/Axio Observer Z1 confocal
microscope.
Mass spectrometry data was collected on a Synapt G2Si (Waters) mass spectrometer.
The data was analyzed using the Waters software UNIFI searching a Waters Lipid Maps
database.
Data format Raw; this manuscript, reference [3] and http://doi.org/10.5281/zenodo.3610075. doi:
10.5281/zenodo.3610075
Analyzed
Parameters for data collection Control, SCD1 and SREBF1 engineered Chinese hamster ovary cells were cultured under
standard batch conditions and transfected to transiently express a range of model
secreted biotherapeutic recombinant proteins.
Description of data collection Western blot and densitometry analysis was undertaken to investigate SCD1 and
SREBF1 expression.
Immunoﬂuorescence analysis was undertaken to analyze expression and cellular
localization of SCD1 and SREBF1.
Cell counting was undertaking to determine viable cell numbers and culture viability
during batch culture.
An Octet® instrument and western blotting was used to estimate secreted recombinant
protein yields.
Mass spectrometry was undertaken to investigate speciﬁc lipids in control, SCD1 and
SREBF1 engineered cells.
Data source location Institution: University of Kent City/Town/Region: Canterbury
Country: UK
Data accessibility With the article, and/or in Refs. [1,3], and in the Zendo data repository; https://doi.org/
10.5281/zenodo.3610075.
Related research article Budge JD, Knight TJ, Povey J, Roobol J, Brown IR, Singh G, Dean A, Turner S, Jaques CM,
Young RJ, Racher AJ, Smales CM (2020) Engineering of Chinese hamster ovary cell lipid
metabolism results in an expanded ER and enhanced recombinant biotherapeutic
protein production, Metabolic Engineering, 57:203e216. https://doi.org/10.1016/j.
ymben.2019.11.007.
Value of the Data
 The data in this work is on the expression and cellular localization of exogenous SCD1 and SREBF1 in Chinese hamster
ovary (CHO) cells, and the impact on the transient yield of model secretory biotherapeutic proteins from such engineered
cells
 The data reports the impact on the growth of SCD1 and SREBF1 engineered CHO cells during batch culture
 Collectively, these data will beneﬁt those interested in (a) expressing biotherapeutic recombinant proteins in high yields
and quality from mammalian cells, and (b) understanding the role of manipulating lipid metabolism on the lipid
composition of cells and the resulting cellular phenotypes
 These data provide the basis for designing further and novel approaches based around modifying lipid metabolism in
mammalian cells to improve such cells ability to produce higher yields of difﬁcult to express biotherapeutic proteins
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This article reports experimental data on the overexpression of the lipid metabolism modifying
genes stearoyl CoA desaturase 1 (SCD1) and sterol regulatory element binding factor 1 (SREBF1) in Chinese
hamster ovary (CHO) cells and the yields of model secretory recombinant proteins achieved from these
during batch culture in a transient expression mode. A summary of vectors bearing genes for pro-
duction of model recombinant biotherapeutic molecules used during this study is reported (Table 1).
Details of antibodies used for analysis, including the manufacturer and reference, the organism pro-
duced in, its applications in the studies reported in this article and in Ref. [1], and the dilution used, are
outlined in Table 2. Analysis of exogenous SCD1 and SREBF1 protein expression by densitometry of
western blots, and the cellular localization by immunoﬂuorescence, is reported in Fig. 1. The raw
Western blot and microscopy image ﬁles can be found in the Zendo data repository [3]. The batch-
culture growth proﬁles of control and SCD1 or SREBF1 engineered cells are shown along with the
proﬁles when such cells are used to create stable model secretory recombinant protein expressing cell
pools in Fig. 2. Analysis of transient secreted recombinant protein yields achieved from control and
SCD1 and SREBF1 engineered CHO cell pools is analyzed in Fig. 3. Analysis of the yield of a protein
considered by the authors to be difﬁcult to express when transiently expressed in CHO cells alongside
lipid metabolism modifying genes is shown in Fig. 4. Analysis of speciﬁc cellular lipids in control and
lipid metabolism modifying engineered CHO cells using mass spectrometry is also reported in Fig. 5.
The raw mass spectrometry data ﬁles can be found in the Zendo data repository ([3] doi: 10.5281/
zenodo.3610075).
2. Experimental design, materials, and methods
2.1. Cloning and construction of vectors used for cell engineering and transient experiments
A summary of the details of vectors generated during this study is described in Table 1. The CHO
speciﬁc SCD1 gene sequence was ampliﬁed via polymerase chain reaction (PCR) using cDNA from
Lonza's CHOK1SV™ cell line as the template and the primers 50-TATGGTACCATGCCGGCC-3’ (forward)
and 50-ATACTCGAGCGGCTACTCTT-3’ (reverse). The SREBF1mouse gene sequence was isolated from anTable 1
A summary of vectors bearing genes for production of model recombinant biotherapeutic molecules used and in Budge et al. [1].
The type of recombinant molecule produced by the vector and number of genes required for expression of these molecules are
outlined. The ﬁgures inwhich the vectors have been used and a brief description of themethod bywhich they have been utilized
are summarized.
Vector Recombinant Molecule Type No. of Genes Brief Method
cB72.3 IgG4 2 Vector used to generate cells stably expressing cB72.3
molecule using hosts previously engineered to
overexpress LMM molecules.
Vector used to transiently produce cB72.3 molecule.
Fc-Fusion
Protein
Fc fusion protein (FcFP) 1 Vector used to generate cells stably expressing an Fc
fusion protein using hosts previously engineered to
overexpress LMM molecules.
Vector used to transiently produce an Fc fusion protein.
IL2-F-Control Interleukin 2 fused bispeciﬁc
antibody
3 plus LMM gene Vectors bearing both IL2-F genes and LMM genes used
to transiently co-transfect.IL2-F-SCD1
IL2-F-SREBF1
IL-2-F Interleukin 2 fused bispeciﬁc
antibody
3 Vector used to generate cells stably expressing IL2-F
molecule using hosts previously engineered to
overexpress LMM molecules.
DTE-IgG1 IgG1 2 Vector used to generate cells stably expressing DTE-
IgG1 molecule using hosts previously engineered to
overexpress LMM molecules.
Table 2
Details of antibodies used for analysis including the manufacturer and reference, the organism produced in and its applications
reported in this article and Budge et al. [1], and the dilution used.
Antibody Company/Catalogue Number Produced In Use and Dilution
Primary Antibodies
Anti-V5 Sigma/V8012 Mouse Immunoﬂuorescence- 1:500
Anti-calnexin Abcam/ab22595 Rabbit Immunoﬂuorescence- 1:200
Anti-g chain Sigma/I9764 Rabbit Western Blot- 1:2000
Anti-SCD1 Cell Signalling/2438 Rabbit Western Blot- 1:1000
Anti-SREBP1 Abcam/ab3259 Mouse Western Blot- 1:1000
Anti-L7a Kind gift from Dr. Anne Roobol Rabbit Western Blot (used at supplied
concentration)
Secondary Antibodies
Anti-Mouse FITC conjugate Sigma/F0257 Goat Immunoﬂuorescence 1:250
Anti-Rabbit FITC conjugate Sigma/F9887 Goat Immunoﬂuorescence 1:250
Anti-Mouse HRP Peroxidase conjugate Sigma/A4416 Goat Western Blot- 1:2000
Anti-Rabbit HRP Peroxidase conjugate Sigma/A6154 Goat Western Blot- 1:2000
J.D. Budge et al. / Data in brief 29 (2020) 1052174OriGene (Rockville, MD) derived vector bearing the cDNA clone for the mouse SREBF1 gene (OriGene
CAT no. MC205184, NCBI accession no. NM_011480) and ampliﬁed via PCR using the primers 50-
TATGCGGCCGCATGGACGAG-3’ (forward) and 50-ATATCTAGACTGCTGGAAGTGACGGTGGTTC-3’
(reverse). SCD1 or SREBF1 genes were cloned into the pcDNA3.1V5-His/TOPO vector (Thermo Fisher
Scientiﬁc) using KpnI and XhoI or NotI and XbaI restriction enzymes respectively (as underlined in
oligonucleotide sequences) in order to generate vectors with the capacity to overexpress the genes of
interest which were in frame with the V5 tag in CHO cells. The SREBF1 CHO cell gene sequence (NCBI
accession no. NM_001244003.1) was synthesized by GeneART (ThermoFisher Scientiﬁc, USA).
Vectors were also constructed for the expression of model secretory recombinant proteins to assess
the impact of cell line engineering on the secreted expression of these model molecules. In particular,
we generated vectors from an in-house Lonza vector for a chimeric B72.3 (cB72.3) antibody as a model
IgG4molecule (considered to be easy to express by the authors) and a second Lonza vector was utilized
which contained sequences for appropriate expression of a model Fc-fusion protein (FcFP). A vector for
expression of a model IgG1 antibody (DTE-IgG1) considered by the authors to be difﬁcult to express
was also constructed. The construction of vectors for expression of an interleukin-2 fused bispeciﬁc
antibody (IL2-F), containing the three genes required for expression of the IL2-F molecule, were built
by having the individual genes synthesized by GeneARTand then cloning these into a Lonza expression
vector where each gene was under the control of a CMV promoter. Variations of the IL2-F vector were
also generated such that they also contained sequences for appropriate expression of lipid metabolism
modifying (LMM) genes SCD1 (IL2-F-SCD1) or SREBF1 (IL2-F-SREBF1), under the control of a CMV
promoter, or a control (IL2-F-Control) lacking any LMM genes but inclusive of an empty expression
cassette. All vectors contained a glutamine synthetase (GS) gene under the control of an SV40 promoter
for use as a metabolic selection marker where necessary.2.2. Cell culture and cell line construction
The process by which stably expressing SCD1 and SREBF1 cell pools and clones were established is
described elsewhere [1] as is the process for generating stable recombinant protein secreting cell pool
and lines. For the purpose of establishing the growth proﬁles of cell pools and lines under batch culture
conditions, cultures were initially seeded with 0.2  106 viable cells/ml in 20 ml of CD-CHO medium
(ThermoFisher Scientiﬁc) and then cultured in a 5% CO2 balanced air environment in a shaking incu-
bator at 140 rpm at 37 C. Cell concentrations and culture viabilities were routinely determined using a
ViCell (Beckman Coulter) instrument and 1ml of culture sample. Culture viability was calculated as the
number of viable cells as a proportion of total cells.
Fig. 1. Quantitative analysis of relative overexpression levels and cellular localization of SCD1 and SREBF1 in engineered cells.
Figure A shows the relative abundance of SCD1 as calculated using densitometry from the western blots reported in Fig. 2A and B of
[1], whilst ﬁgure B shows the relative abundance of SREBF1 species. The values have been normalized to L7a loading control and
subsequently normalized to either CHO-SCD1POOL (A) or CHO-SREBF1POOL (B) values. Cellular localization of overexpressed SCD1 and
SREBF1 proteins in CHO-ControlPOOL, CHO-SCD1POOL and CHO-SREBF1POOL cell pools as determined by immunoﬂuorescent detection
using an anti-V5 antibody conjugated with a FITC secondary antibody (C). An anti-calnexin antibody conjugated with a TRITC
secondary antibody was used to highlight the position of the ER. Images were obtained using confocal microscopy.
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Fig. 2. Growth proﬁles of CHOK1SV GS-KO™ cells engineered to overexpress lipid metabolism modifying genes SCD1 and
SREBF1. Batch cultures were seeded at 0.2  106 viable cells/ml in a total culture volume of 20 ml and cell concentrations measured
using a ViCell every 24 h. The CHO-ControlPOOL growth proﬁle is shown in A-D for reference whilst lipid metabolism modiﬁed pool
data are shown in (A), control monoclonal measurements are shown in (B), SCD1 monoclonal samples are shown in (C) and SREBF1
monoclonal measurements are shown in (D). Cell pools were constructed using lipid modiﬁed polyclonal cell pools as hosts such
that they stably express either the cB72.3 monoclonal antibody or FcFP molecule. Growth proﬁles of these cells are shown in
Figure (E) for cB72.3 expressing pools and Figure (F) for FcFP expressing pools. n ¼ 3 for each data point and error bars show ± one
standard deviation.
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Fig. 3. Product analysis post transient transfection in lipid modiﬁed cells. Previously engineered host cells (CHO-ControlPOOL,
CHO-SCD1POOL, CHO-SREBF1POOL) were transiently transfected with vectors containing genes for expression of either cB72.3 (A and
B) or FcFP (C and D). Quantitative analysis using an Octet® was carried out on supernatant samples harvested at 24, 48, 72 and 96 h
post transfection for cB72.3 (A) and FcFP (C) transfections. Western blot analysis of cB72.3 (B) and FcFP (D) molecules were carried
out on supernatant samples harvested at 96 h, and 48 h in the case of cB72.3. n ¼ 3 for each data point and error bars show ± one
standard deviation.
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Fig. 4. Product analysis post transient transfection with vectors bearing genes for a recombinant product and a lipid modi-
fying gene on the same expression vector. Vectors containing genes necessary for expression of an antibody fusion molecule (IL2-
F) with either no additional LMM gene (IL2-F-Control), the SCD1 gene (IL2-F-SCD1) or the SREBF1 gene (IL2-F-SREBF1) on the same
vector. Quantitative analysis using an Octet®was carried out on supernatant samples harvested at 96 h post transfection to measure
relative product concentration (A). Western blot analysis was also carried out on reduced samples. A heavy chain band (approxi-
mately 50 kDa) and an antibody heavy chain-IL2 fusion band (approximately 70 kDa) associated with the antibody fusion molecule
is observed (B). n ¼ 3 for each data point and error bars show ± one standard deviation.
J.D. Budge et al. / Data in brief 29 (2020) 10521782.3. Transient expression of secretory recombinant biotherapeutic proteins
Transient transfections were performed using a GenePulser Xcell electroporator (Bio-Rad). Vector
DNA (20 mg) diluted in 100 ml TE buffer and 700 ml of cells (1107 viable cells) were added to a cuvette.
The DNA/cell mix was electroporated at 300 V and 900 mF in a cuvette with a 0.4 mm electrode gap.
Medium (1 ml at 37 C) was then added to the cuvette immediately after electroporation. The elec-
troporated cells were then added to a ﬂask containing 17.2 ml CD-CHO medium and a further 1 ml of
mediumwas used to wash the cuvette and added to the culture such that a ﬁnal volume of 20 ml was
achieved in a 125 ml Erlenmeyer ﬂask (Corning®). Cells were cultured in a 5% CO2 balanced air
environment and batch transient cultures were incubated in a shaking incubator at 140 rpm at 37 C.2.4. Western blotting
Western blotting was undertaken as described elsewhere [2] and the details of the primary and
secondary antibodies used in this study are outlined in Table 2. Quantitative densitometry was
analyzed using ImageJ software.2.5. Lipid extraction from cells and mass spectrometry analysis
The process for extracting lipids for analysis by mass spectrometry from cultured CHO cells and the
process for the analysis of the mass spectrometry data is described in Ref. [1].2.6. Immunoﬂuorescence analysis
Cells were analyzed by immunoﬂuorescence to determine the expression of exogenous ectopic
SCD1 and SREBF1, and the localization of these proteins. The procedure for such analysis is described in
Fig. 5. Analysis of speciﬁc cellular lipids in control and LMM engineered CHO cells using mass spectrometry. Figures A to D
show relative quantities of speciﬁc lipid species as indicated by ion intensities at speciﬁc retention times. Stars represent data
obtained from SCD1 high samples which are either upregulated (A and B), downregulated (D), or unchanged (C) compared to the
control and other SCD1 engineered cell pools and clones. Retention times (RT) and m/z ions are indicated within the ﬁgure.
J.D. Budge et al. / Data in brief 29 (2020) 105217 9Ref. [1] and the antibody details described in Table 2. Images were captured using a Zeiss LSM 880/
Elyra/Axio Observer Z1 confocal microscope instrument.2.7. Determination of secreted recombinant protein concentrations
Secreted recombinant protein concentrations in cell culture supernatants were determined using
an Octet® instrument (ForteBio) with IgG calibrators and protein A biosensors.Acknowledgments
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